Chakraborty Tirtha

SEC source: 0001415889-25-012225 · form4-05072025_080556.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · Chief Sci Off & Head Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,416

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-25-011805 · form4-05022025_080533.xml · nonDerivative · entry 2

Chakraborty Tirtha · CIK 0001840685 · Chief Sci Off & Head Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 218,292

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-25-011805 · form4-05022025_080533.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · Chief Sci Off & Head Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 219,254

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-25-003368 · form4-02072025_090235.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,239

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 19

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 315,000

Underlying: Common Stock · 315,000 shares

Expires 2035-02-02

F11 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2025, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 18

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,500

Underlying: Common Stock · 107,500 shares

Expires 2034-01-28

F5 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F10 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 17

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 107,500 shares

Expires 2034-01-28

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F10 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 16

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,500

Underlying: Common Stock · 95,500 shares

Expires 2033-02-05

F5 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F9 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 15

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 95,500 shares

Expires 2033-02-05

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F9 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 14

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,000

Underlying: Common Stock · 76,000 shares

Expires 2032-08-31

F5 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F8 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 24 successive equal monthly installments beginning on October 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 13

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 76,000 shares

Expires 2032-08-31

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F8 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 24 successive equal monthly installments beginning on October 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 12

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,000

Underlying: Common Stock · 101,000 shares

Expires 2032-01-31

F5 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F7 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 11

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 101,000 shares

Expires 2032-01-31

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F7 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 10

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,323

Underlying: Common Stock · 121,323 shares

Expires 2030-11-17

F5 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F6 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on December 16, 2020, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 9

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 121,323 shares

Expires 2030-11-17

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F6 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on December 16, 2020, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 8

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,656

Underlying: Common Stock · 70,656 shares

Expires 2030-08-20

F5 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 7

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 70,656 shares

Expires 2030-08-20

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 6

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,410

Underlying: Common Stock · 24,410 shares

Expires 2030-03-09

F5 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 5

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,410 shares

Expires 2030-03-09

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 4

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,800

Underlying: Common Stock · 28,800 shares

Expires 2029-09-24

F5 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · derivative · entry 3

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,800 shares

Expires 2029-09-24

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · nonDerivative · entry 2

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,272

F2 · shares: Represents the number of shares underlying RSUs. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2025, subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-25-003175 · form4-02062025_020213.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,772

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").

SEC source: 0001415889-24-026431 · form4-11082024_041109.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,935

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-026131 · form4-11052024_041119.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,810

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-022770 · form4-09042024_040916.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,796

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-020987 · form4-08082024_080826.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,372

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-020737 · form4-08052024_040806.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,248

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-012458 · form4-05072024_040505.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,233

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-012156 · form4-05032024_040512.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,108

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-006593 · form4-03052024_040326.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,093

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-003033 · form4-02082024_100204.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,669

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-002101 · form4-02012024_120240.xml · derivative · entry 2

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,500

Underlying: Common Stock · 107,500 shares

Expires 2034-01-28

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-24-002101 · form4-02012024_120240.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,702

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2024, subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-23-054702 · doc4.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,952

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001209191-23-048385 · doc4.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,828

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001209191-23-045196 · doc4.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,404

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").

SEC source: 0001209191-23-028466 · doc4.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,279

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").

SEC source: 0001209191-23-014921 · doc4.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,154

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").

SEC source: 0001209191-23-007777 · doc4.xml · derivative · entry 2

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,500

Underlying: Common Stock · 95,500 shares

Expires 2033-02-05

F3 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-23-007777 · doc4.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,730

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning February 6, 2023, subject to the Reporting Person's continued service as of each such date.

F2 · balance_after: Includes 3,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on November 15, 2022.

SEC source: 0001209191-22-048730 · doc4.xml · derivative · entry 2

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,000

Underlying: Common Stock · 76,000 shares

Expires 2032-08-31

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 24 successive equal monthly installments beginning on October 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-22-048730 · doc4.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,980

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in four equal installments on each of March 1, 2023, September 1, 2023, March 1, 2024 and September 1, 2024, in each case, subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-22-006795 · doc4.xml · derivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,000

Underlying: Common Stock · 101,000 shares

Expires 2032-01-31

F1 · derivative.exercise_date: This option vests over four years in equal monthly installments beginning on February 1, 2022.

SEC source: 0001209191-21-052514 · doc4.xml · derivative · entry 2

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,800

Underlying: Common Stock · 17,446 shares

Expires 2029-09-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 1/4th of the shares underlying the option vested on September 23, 2020, with the remainder vesting in equal monthly installments over 3 years, provided that the Reporting Person remains continuously engaged by the Issuer on each such vesting date.

SEC source: 0001209191-21-052514 · doc4.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,980

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-008897 · doc4.xml · derivative · entry 2

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,534 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

SEC source: 0001209191-21-008897 · doc4.xml · nonDerivative · entry 1

Chakraborty Tirtha · CIK 0001840685 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,534

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.